logo
logo

T3 Pharma raises 25M CHF to advance bacterial cancer therapy through clinic

T3 Pharma raises 25M CHF to advance bacterial cancer therapy through clinic

07/22/20, 8:09 AM
T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF.

Company Info

Company
Additional Info
AccelFoods is an early-stage venture fund investing in consumer products. We partner with entrepreneurs to bring innovative, high-quality food and beverage products to the forefront of the industry and create the next generation of enduring brands. With nearly $40m under management, we are hands-on partners that work tactically with our founders to scale their businesses quickly and smartly. We connect the dots within the broader food & beverage ecosystem to provide unique access, share distinct expertise, and build solid infrastructure.

Related People